

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

PC 02120

315403

<p>Licensee</p> <p>1. Saint Joseph Regional Medical Center Plymouth Campus</p> <p>2. 1915 Lake Avenue P.O. Box 670 Plymouth, IN 46563</p>	<p>In accordance with letter dated April 1, 2006.</p> <p>3. License number 13-18880-01 is amended in its entirety to read as follows:</p> <p>4. Expiration date December 31, 2010</p> <p>5. Docket No. 030-17303 Reference No.</p>
---	---

<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Any byproduct material permitted by 10 CFR 35.300</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Any, (excluding iodine-131 for thyroid carcinoma).</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As needed</p> <p>B. As needed</p> <p>C. As needed</p>
--	--	---

<p>9. Authorized Use:</p> <p>A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.</p> <p>B. Any imaging and localization study permitted by 10 CFR 35.200.</p> <p>C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300 (excluding iodine-131 for thyroid carcinoma).</p>	
--	--

CONDITIONS

- 10. Licensed material shall be used only at the licensee's facilities located at 1915 Lake Avenue, Plymouth, Indiana and **2349 Lake Avenue, Suite 201, Plymouth, Indiana.**
- 11. The Radiation Safety Officer for this license is John D. Scheu, Ph.D.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number 13-18880-01
Docket or Reference Number 030-17303
Amendment No. 20

12. Licensed material is only authorized for use by, or under the supervision of:
- A. Individuals permitted to work as an authorized user, authorized nuclear pharmacist, and/or authorized medical physicist in accordance with 10 CFR 35.13 and 35.14.
 - B. The following individuals are authorized users for medical use as indicated:

<u>Authorized Users</u>	<u>Material and Use</u>
Brett A. Stephens, M.D.	10 CFR 35.100, 35.200, and 35.300 (excluding Iodine-131 for treatment of thyroid carcinoma).
Toby Mathews, M.D.	10 CFR 35.100, 35.200 and 35.300 (excluding Iodine-131 for treatment of thyroid carcinoma).
Edward Yang, M.D.	10 CFR 35.100 and 35.200.
Douglas S. Kuehn, M.D.	10 CFR 35.100 and 35.200.
Robert Rust, M.D.	10 CFR 35.100, 35.200 and 35.300 (excluding Iodine-131 for treatment of thyroid carcinoma).
Victor Jones, II, M.D.	10 CFR 35.100 and 35.200.
Michael McCrea, M.D.	10 CFR 35.100, 35.200 and 35.300 (excluding Iodine-131 for treatment of thyroid carcinoma).
David Cory, M.D.	10 CFR 35.100 and 35.200.
Timothy S. Smith, M.D.	10 CFR 35.100, 35.200 and 35.300 (excluding Iodine-131 for treatment of thyroid carcinoma).
Linda L. Tuthill, M.D.	10 CFR 35.100, 35.200 and 35.300.
Steven T. Gerstler, M.D.	10 CFR 35.100 and 35.200.
Vu H. Nguyen, M.D.	10 CFR 35.100 and 35.200.
Paul Shu, M.D.	10 CFR 35.100 and 35.200.

13. Pursuant to Title 10, Chapter 1, Code of Federal Regulations, Part 40, "Domestic Licensing of Source Material," the licensee is authorized to possess, use, transfer, and import up to 999 kilograms of depleted uranium contained as shielding material in the molybdenum-99/technetium-99m generators authorized by this license.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
13-18880-01

Docket or Reference Number
030-17303

Amendment No. 20

14. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
15. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
16. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated April 16, 1990, and
- B. Letters dated January 20, 1993, February 3, 1993, May 8, 1999, June 20, 2000, April 1, 2006 and May 21, 2006.



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date JUN 05 2006

By [Signature]
Toye L. Simmons
Materials Licensing Branch
Region III